SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lincoln Pharmaceuticals soars on getting European Union GMP's nod for Khatraj facility

19 May 2020 Evaluate

Lincoln Pharmaceuticals is currently trading at Rs. 165.00, up by 1.15 points or 0.70% from its previous closing of Rs. 163.85 on the BSE.

The scrip opened at Rs. 165.00 and has touched a high and low of Rs. 168.00 and Rs. 161.35 respectively. So far 97945 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 220.00 on 28-Jan-2020 and a 52 week low of Rs. 85.50 on 19-Mar-2020.

Last one week high and low of the scrip stood at Rs. 168.00 and Rs. 153.05 respectively. The current market cap of the company is Rs. 332.00 crore.

The promoters holding in the company stood at 32.40%, while Institutions and Non-Institutions held 0.28% and 67.33% respectively.

Lincoln Pharmaceuticals has received the European Union (EU) GMP certification from Germany FDA for its manufacturing facility located at Khatraj in Gujarat. The certification will allow the company to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. The company looks to enter the EU markets very soon with its dermatology, gastro and pain management products and gradually expand product portfolio. 

The inspection was done by the regulatory agency in December 2019 followed by final approval in May 2020. The company manufactures wide-range of drugs at its Khatraj facility and includes anti-infective, respiratory system, gynaecology, dermatology, gastro, pain management, cardio & CNS, anti-bacterial, antidiabetic, anti-malaria among others. 

Lincoln Pharmaceuticals is engaged in the manufacture and marketing of affordable therapeutic products. The product range of the company includes Tablets, Capsules, Injectable, Syrups and Ointments.

Lincoln Pharma Share Price

611.90 25.30 (4.31%)
20-Apr-2026 15:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.95
Dr. Reddys Lab 1233.20
Cipla 1231.45
Zydus Lifesciences 937.70
Lupin 2329.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×